S&P Futures
4,274.25 -6.75 (-0.16%) Dow Futures
33,670.00 -48.00 (-0.14%) Nasdaq Futures
13,552.50 -25.25 (-0.19%) Russell 2000 Futures
2,012.50 -4.40 (-0.22%) Crude Oil
91.48 -0.61 (-0.66%) Gold
1,812.70 -2.80 (-0.15%)
Landos Biopharma, Inc. (LABP)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.0800 |
| Open | 1.0500 |
| Bid | 1.0500 x 2200 |
| Ask | 1.1300 x 800 |
| Day's Range | 1.0000 - 1.0700 |
| 52 Week Range | 0.5500 - 16.1700 |
| Volume | |
| Avg. Volume | 104,243 |
| Market Cap | 44.443M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update
Positive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety and Tolerability Profile Across Range of Once-Daily Oral Doses, as well as Promising Early Efficacy Signals Phase 2 Proof of Concept Clinical Trial for NX-13 in Ulcerative Colitis Planned On Track to Complete Comprehensive Review of Clinical Development Plans Later this Year NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical c
- GlobeNewswire
Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial
NX-13 Demonstrated Favorable Safety and Tolerability Profile Across Range of Once-Daily Doses Results Indicate Promising Early Signals Regarding the Efficacy of NX-13 Phase 2 Proof of Concept Clinical Trial in Ulcerative Colitis Planned NEW YORK, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced positive top-line results from its Phase 1b clini
- GlobeNewswire
Landos Names Gregory Oakes President and Chief Executive Officer
Seasoned Pharmaceutical Executive Brings 25+ Years of Experience With a Focus on Successful Commercialization Company Remains On Track to Complete Review of Clinical Development Plans Later This Year NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that Gregory Oakes has been named President and Chief Executive Officer, and has been
